Cancer and Heart Disease; Screening During COVID; CBD for Smoking Cessation

The American Cancer Society has advice about how the more than 18 million adult cancer survivors can reduce their risk of developing heart disease.

Some reassuring data about COVID and cancer screening: Missed screenings during the pandemic have not translated into increased rates or more advanced-stage diagnoses for most common types of cancer. (Epic Research)

Jasper Therapeutics announced favorable early-stage results for its c-Kit-targeting antibody briquilimab for patients with hematologic malignancies.

Currently available breast cancer risk-assessment models may incorrectly classify a substantial proportion of women. (David Geffen School of Medicine at UCLA, Journal of General Internal Medicine)

An investigational urine-based test has shown early promise for early diagnosis of pancreatic cancer and possibly other types of malignancies. (Korea Institute of Materials Science, Biosensors and Bioelectronics)

Application of an artificial intelligence information processing technique significantly improved prediction for risk of prostate cancer recurrence after definitive treatment. (American Journal of Pathology)

Adding a blood pressure medication to chemotherapy appeared to improve anticancer activity in pancreatic cancer by reducing immunosuppression and inhibiting genes that promote tumor invasion. (Mass General Cancer Center, Clinical Cancer Research)

Laboratory studies suggest that reduced CD5 expression by dendritic cells in tumors may identify patients who are unlikely to benefit from cancer immunotherapy. (Washington University in St. Louis, Science)

Can CBD products succeed where other interventions have failed to improve smoking cessation rates? (Washington State University, Chemical Research in Toxicology)

Julia Beaver, MD, second in command at the FDA Oncology Center of Excellence, departed the agency to become senior vice president at San Diego-based Treeline Biosciences. (Endpoints News)